EVOLOCUMAB LOWERS LOW DENSITY LIPOPROTEIN CHOLESTEROL AND LIPOPROTEIN (A) LEVELS IN NEPHROTIC SYNDROME. Ramarao Pradeep
|
|
- Anastasia Nash
- 6 years ago
- Views:
Transcription
1 AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset and finalized. This version of the manuscript will be replaced with the final, published version after it has been published in the print edition of the journal. The final, published version may differ from this proof. Case Report ACCR EVOLOCUMAB LOWERS LOW DENSITY LIPOPROTEIN CHOLESTEROL AND LIPOPROTEIN (A) LEVELS IN NEPHROTIC SYNDROME Ramarao Pradeep From: Endocrine Associates of Quad Cities Running title: Evolocumab lowers Lp(a) in nephrotic syndrome Corresponding address: Dr. Ramarao Pradeep, Endocrine Associates of Quad Cities, 612, 35th Avenue, Moline,Illinois
2 Abstract Objectives: To present a patient with nephrotic syndrome and elevated Low density lipoprotein cholesterol secondary to increased Lipoprotein (a) levels and to demonstrate a decrease in Lp(a) levels secondary to Evolocumab therapy. Methods: Lp(a) was measured by immunoturbidimetric assay. The elevated Lp(a) level was treated with Evolocumab. Results: A 56-year-old man with coronary artery disease and peripheral vascular disease presented with elevated LDL cholesterol. Physical examination revealed grade 4+ pitting pedal edema. Twenty-four-hour urine protein collection revealed proteinuria in the nephrotic range. The fasting LDL cholesterol level on a combination of high intensity statins,ezetimibe and lifestyle changes was 156 mg/dl (4.04mmol/L), and the fasting Lp(a) level was 130 mg/dl(4.641µmol/l). Treatment with Evolocumab resulted in a 73 % reduction in Lp(a) and a concomitant 76.9% reduction in LDL -cholesterol. Conclusions: Nephrotic syndrome increases the Lp(a) level. Lp(a) contains cholesterol that is not differentiated from LDL cholesterol by current LDL- cholesterol measurement methods. Hence, Lp(a)-corrected LDL cholesterol should be used in patients with increased Lp(a). Evolocumab decreased the Lp(a) levels by 73% thereby providing the correct estimation of LDL-C. Abbreviations: LDL-C = LDL cholesterol; Lp(a) = lipoprotein(a); PCSK9 = proprotein convertase subtilisin/kexin type 9; HDL = high density lipoprotein; ASCVD = atherosclerotic vascular disease; CETP = cholesteryl ester transfer protein.
3 Introduction Low density lipoprotein- cholesterol accounts for 75% of the cholesterol carried by non-high density lipoprotein cholesterol particles (Intermediate density lipoprotein, LDL-C, Very low density lipoprotein- cholesterol, Chylomicron remnants, and Lipoprotein(a)). LDL-C can be calculated using Friedewald equation (LDL = total cholesterol - (HDL + triglycerides / 5), which include the cholesterol carried by Lp(a). Similarly, direct LDL-C measurements do notdifferentiate cholesterol derived from Lp(a). Patients with nephrotic syndrome have high concentrations of Lp(a) (1). Overall, 45% of Lp(a) is cholesterol, and current LDL measurement methods do not separately report cholesterol derived from Lp(a). We report a case of a 56-year-old man with elevated Lp(a) that resulted in pseudo-elevation of LDL-C that was corrected with Evolocumab. The degree of decrease in Lp(a) following treatment with Evolocumab observed in our patient has not been previously reported. Case Presentation The patient was a 56-year-old man with a history of type 2 diabetes, coronary artery Disease and peripheral vascular disease who presented for lipid evaluation. He was using 5 units of insulin aspart with dinner, glipizide with breakfast and insulin detemir (23 units daily). His blood sugar levels ranged from to 6.05 mmol/l (75 to 110 mg/dl). The patient did not have diabetic retinopathy. The nephrotic syndrome was likely secondary to hypertensive nephrosclerosis. His cardiac history was significant for inferior wall myocardial infarction 4 years prior to presentation. An angiogram one year prior showed a 50-60% occlusion of the right coronary artery and chronic occlusion of the left anterior descending artery. He also had a history of peripheral vascular disease with an aortofemoral bypass. His family history was negative for coronary artery disease and peripheral vascular disease. He was taking aspirin 325 mg, atorvastatin 80 mg daily and ezetimibe. In addition, he used 2 gm of plant sterols and stanols and was on a less than 10% saturated fat diet. He could not
4 exercise regularly due to shortness of breath.the laboratory data showed an a1c of 6.7 %(50 mmol/mol). His fasting LDL-C level was 156 mg/dl(4.04mmol/l). His non- HDL cholesterol was 254 mg/dl (6.56 mmol/l).the Lp(a) was 130 mg/dl(4.641µmol/l). His thyroid stimulating hormone was 0.89 U/L. The 24 hour urine protein collection equaled 6.6 grams/24 hours. The glomerular filtration rate was 23 ml/min. The serum albumin was 2.9 grams/l. He was started on Evolocumab at 140 mg every 2 weeks. After 3 months of Evolocumab therapy, LDL- C decreased to 36 mg/dl(0.93 mmol/l). Lp(a) had decreased to 35 mg/dl(1.25 µmol/l). Non HDL cholesterol decreased to 57 mg/dl(1.47 mmol/l) Physical Examination The physical examination showed the following: height: 59 inches, weight: 168 lbs., BMI: kg/m2, blood pressure: 120/80 mmhg and waist circumference: 104 cm. Periorbital edema was present. A neck exam showed no goiter. The lungs were clear upon auscultation. He had normal heart sounds without murmurs and grade 4+ pitting pedal edema.there was no evidence of palmar xanthomas or tendon xanthomas. Peripheral vascular examination showed 2+ dorsalis pedis and posterior tibial pulses. Discussion On atorvastatin 80 mg and ezetimibe 10 mg daily, the patient had an LDL cholesterol of 156 mg/dl(4.04g/l). Hypothyroidism was ruled out. Lack of familial history of cardiovascular diseases meant that proteinuria was the most likely cause of mixed hyperlipidemia and elevated Lp(a). Obesity with visceral adiposity may explain the increased LDL-C levels. However, it does not contribute to the elevated Lp(a). Additionally, while chronic kidney disease is an important cause of cardiovascular disease, it did not cause his elevated Lp(a). Lipoprotein (a) consists of apolipoprotein A attached to LDL by a disulfide bond to apolipoprotein B. Lp(a) carries a load of oxidized phospholipids. It inhibits the
5 conversion of plasminogen to plasmin, thereby increasing thrombogenesis and atherogenicity. Based on the number of Kringle IV repeats, the molecular weight of Lp(a) can vary from 300,000 to 800,000 Daltons. The low molecular weight phenotype is associated with a greater number of Lp(a) particles and correlates with increased cardiovascular disease risk (1). A preponderance of the low molecular weight phenotype exists in patients with nephrotic syndrome (1). It is the low molecular weightphenotype that is associated with elevated LDL-C (1). Forty-five percent of Lp (a) is composed of cholesterol. In a classic example from the literature, if the Lp(a) level is 200 mg/dl (7.14 µmol/l) and the measured LDL level is 200 mg/dl (5.18 mmol/l), the actual LDL-C would be 110 mg/dl(2.85 mmol/l) (1). Therefore, if Lp(a) is elevated, 45% of the Lp(a) level needs to be subtracted from the LDL-C value to obtain the true LDL-C level (1) A low serum albumin level results in low plasma oncotic pressure. The low oncotic pressure stimulates apolipoprotein B gene transcription (2). Hence, patients with nephrotic syndrome have elevated total cholesterol, LDL-C, triglycerides, and Lp(a) levels. This patient did not have any family history of cardiovascular or peripheral vascular disease. Hence, the most likely cause of elevated Lp(a) in this patient was nephrotic syndrome. The effect of lowering LDL-C and the risk improvement in ASCVD have been well documented in genetic studies and after pharmacological intervention. Individuals with loss-of-function mutations in the proprotein convertase subtilisin kexin type 9 (PCSK9) gene have low levels of LDL-C and a markedly reduced risk for ASCVD events (3, 4). The Cholesterol Treatment Trialist metaanalysis demonstrated that for every 1 mmol/l (38.7 mg/dl) decrease in LDL-C, there was a 22% relative risk reduction for major ASCVD events. Larger reductions on the order of 2-3 mmol/l ( mg/dl) resulted in a 40-50% relative risk reduction for ASCVD (5). Unfortunately, neither diet nor commonly used anti-lipid agents such as statins, bile acid binding resins and ezetimibe affect Lp(a) levels. Drugs that decrease the Lp(a) level include aspirin and lipid lowering agents- such as niacin, mipomersen, lomitapide, CETP inhibitors and PCSK9 inhibitors. Niacin was not used in this patient because of its tolerability and safety profile. The CETP inhibitor anacetrapib decreases Lp (a) by approximately 40-50% (7). However,
6 anacetrapib is not currently approved for the treatment of elevated Lp(a). Mipomersen and Lomitapide are approved for the treatment of familial hypercholesterolemia only. In a patient with ischemic stroke and elevated Lp(a), aspirin reduced the Lp(a) levels by 15% (8). Our patient had been taking 325mg aspirin for four years. Hence, it was unlikely that aspirin contributed to the acute decrease in the Lp(a) level. The decrease in Lp(a) cholesterol was likely due to the addition of Evolocumab. The magnitude of decrease in Lp(a) observed in this patient has not been previously reported in the literature and it is similar to the reduction in Lp(a) levels by LDL apheresis. PCSK9 is a protein secreted by the liver that binds to the LDL receptor and targets it for lysosomal degradation (6). Therefore, inhibition of PCSK9 is an important target in the treatment of elevated LDL-C. In the FOURIER trial, patients with diabetes at baseline whoreceived Evolocumab demonstrated an absolute reduction of 56 mg/dl(1.44 mmol/l)in the level of LDL-C. In the subgroup with diabetes at baseline, a 16% reduction in triglycerides and a 49.5% reduction in non-hdl cholesterol level were observed (9). In addition, a 17% decrease was observed in the primary efficacy endpoint of major cardiovascular events. Defined as a composite of cardiovascular deaths, myocardial infarction, stroke, and hospitalization due to unstable angina or coronary revascularization. In this trial, Evolocumab reduced Lp(a) by 26.9%. This patient demonstrated a robust reduction in Lp(a) due to Evolocumab therapy Postulated mechanisms by which PCSK9 inhibitors decrease Lp(a) include decreased synthesis of apolipoprotein B-100 particles, increased expression of SRB1 scavenger receptors and clearance of Lp(a) by SRB1 scavenger receptors or increased degradation of Lp receptor-related proteins (10) This case has important implications for statin use. First, statins do not affect Lp(a) levels.second, the American Heart Association divides patients into statin benefit groups (11). In such a case, statin effectiveness is decided by the percentage decrease in LDL-C. A patient with an LDL-C level that is not corrected for elevated Lp(a) will be recommended higher doses of statins, addition of non-statins, or both. In patients with chronic kidney disease,higher doses of stains can increase the risk of
7 statin-related myalgia/myositis, thereby increasing the potential for statin noncompliance in a group of patients in need of statins. In conclusion,it is important to recognize that patients with nephrotic syndrome have elevated levels of Lp(a). Lp(a)- corrected LDL-cholesterol needs to be used in cardiovascular risk assessment in patients with Nephrotic syndrome. Evolocumab lowers Lp(a) and helps in an accurate assessment of LDL-C.. Funding: None Conflict of Interest: None
8 References 1. Kronenberg, F, Lingenhel A, Lhotta K, et al. Lipoprotein(a) and lowdensity lipoprotein-derived cholesterol innephrotic syndrome: Impact on lipid-lowering therapy. Kidney Int. 2004;66: Yamaguchi, A, Fukuhara Y, Yamamoto S, et al. Oncotic pressure regulates gene transcriptions of albumin and apolipoprotein B in cultured rat hepatoma cells. Am J Physiol. 1992;263:C397-C Cohen JC, Boerwinkle E, Mosley TH Jr, Hoobs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354: Seidah NG, Awan Z, Chretien M, Mbikay M. PCSK9: A key modulator of cardiovascular health. Circ Res. 2014;114: Cholesterol Treatment Trialists (CTT) Collaboration, Baigent C, Blackwell L, Emberson J. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376: Seidah NG, Awan Z, Chretien M, Mbikay M. PCSK9: A key modulator of cardiovascular health. Circ Res. 2014;114: Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009; 157: e 8. Lakshminarayan D, Elajami TK, Devabhaktuni S, Welty FK. Ischemic Stroke in young Adult with elevated lipoprotein (a): A case report and review of literature. J Clin Lipidol. 2016;10:
9 9. MS Sabatine, LA Leiter, SD Wiviott, RP Giugliano, P Deedwania, GM De Ferrari, SA Murphy, JF Kuder, AC Keech, PS Sever, and TR Pedersen, for the FOURIER Steering Committee & Investigators. Cardiovascular efficacy and safety of evolocumab in diabetes, and risk of development of diabetes. In: European Association of Diabetes- 53rd Annual Meeting. Clinical Trial Update. September 15th, Kotani K, Banach M. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9. J Thorac Dis. 2017;9:E78-E Stone NJ, Robinson JG, Lichtenstein AH, et al ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;63:
Drug Class Monograph
Drug Class Monograph Class: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Drugs: Praluent (alirocumab), Repatha (evolocumab) Line of Business: Medi-Cal Effective Date: February 17, 2016
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationADMINISTRATIVE POLICY AND PROCEDURE
ADMINISTRATIVE POLICY PROCEDURE Policy #: Subject: PCSK9 INHIBITS (ex: Repatha) Section: Care Management Effective Date: January 1, 2015 Revision Date(s): NA Review Date(s): NA Responsible Parties: Patryce
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationPharmacy Management Drug Policy
SUBJECT: ; Praluent (alirocumab), Repatha (evolocumab) POLICY NUMBER: Pharmacy-61 EFFECTIVE DATE: 8/15 LAST REVIEW DATE: 9/22/2017 If the member s subscriber contract excludes coverage for a specific service
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationRequest for Prior Authorization for PCSK9 inhibitor therapy Website Form Submit request via: Fax
Request for Prior Authorization for PCSK9 inhibitor therapy Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 PCSK9 is a protein that reduces the hepatic removal of low-density
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationLipid Metabolism in Familial Hypercholesterolemia
Lipid Metabolism in Familial Hypercholesterolemia Khalid Al-Rasadi, BSc, MD, FRCPC Head of Biochemistry Department, SQU Head of Lipid and LDL-Apheresis Unit, SQUH President of Oman society of Lipid & Atherosclerosis
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationLDL How Low can (should) you Go and be Safe
LDL How Low can (should) you Go and be Safe Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Definition of Low LDL National Health and
More informationPCSK9 Inhibitors: Promise or Pitfall?
PCSK9 Inhibitors: Promise or Pitfall? Tracy Harlan, PharmD PGY2 Ambulatory Care Resident University of Iowa Hospitals and Clinics tracy harlan@uiowa.edu Tracy Harlan does not have any actual or potential
More informationLipids Board Review. Ira Goldberg, MD New York University School of Medicine. Which of the following is the best initial therapy choice?
Lipids Board Review Ira Goldberg, MD New York University School of Medicine 1. A 22 year old male college student is referred for severe hypertriglyceridemia ( 1500 mg/dl [ 17.0 mmol/l]). He has a history
More informationEVIDENCE TO DATE EVOLOCUMAB (REPATHA)
and Clinical Outcomes in Patients with Cardiovascular Disease, March 2017 1 CLINICAL QUESTION In patients with atherosclerotic cardiovascular disease and LDL >1.8mmol/L or non-hdl > 2.6mmol/L, how does
More informationPCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia
PCSK9 Inhibitors Praluent (Alirocumab) and Repatha (Evolocumab) For the Treatment of Familial Hypercholesterolemia Policy Number: Original Effective Date: MM.04.037 08/01/2016 Line(s) of Business: HMO;
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationPCSK9 Inhibitors DRUG POLICY BENEFIT APPLICATION
DRUG POLICY BENEFIT APPLICATION PCSK9 Inhibitors Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Original Article and Clinical Outcomes in Patients with Cardiovascular Disease Marc S. Sabatine, M.D., M.P.H., Robert P. Giugliano, M.D., Anthony C. Keech, M.D., Narimon Honarpour, M.D., Ph.D., Stephen
More informationCardiovascular Controversies: Emerging Therapies for Lowering Cardiovascular Risk
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS
ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS Ziyad Ghazzal MD, FACC, FSCAI Professor of Medicine Deputy Vice President/Dean Associate Dean for Clinical Affairs American University of Beirut Adjunct
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationSupplementary Online Content
Supplementary Online Content Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of lipid-lowering therapy intensification in a population with atherosclerotic cardiovascular
More informationDrug Therapy Guidelines
Drug Therapy Guidelines PCSK9 Inhibitors: Praluent TM, Repatha TM Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 10/9/15
More informationClinical Policy: Evolocumab (Repatha) Reference Number: CP.CPA.269 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Repatha) Reference Number: CP.CPA.269 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationMartin/Hopkins Estimation, Friedewald and Beta- Quantification of LDL-C in Patients in FOURIER
TAP TO GO BACK TO KIOSK MENU Seth S. Martin, M.D., M.H.S., Robert P. Giugliano, M.D., S.M., 2 Sabina A. Murphy, M.P.H., 2 Scott M. Wasserman, M.D., 3 Peter S. Background Evolocumab, a fully human monoclonal
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More informationPraluent (alirocumab)
Praluent (alirocumab) Policy Number: 5.01.600 Last Review: 06/2018 Origination: 07/2015 Next Review: 06/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Praluent
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationPCSK9 Inhibition: From Genetics to Patients
PCSK9 Inhibition: From Genetics to Patients John Chapman BSc, Ph.D., D.Sc., FESC Research Professor, University of Pierre and Marie Curie Director Emeritus, INSERM Dyslipidemia and Atherosclerosis Research
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationPathophysiology of Lipid Disorders
Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history
More informationCase Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic
Case Discussions: Treatment Strategies for High Risk Populations Peter H. Jones MD, FNLA Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Most Common Reasons for
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationabstract n engl j med 376;18 nejm.org May 4,
The new england journal of medicine established in 1812 May 4, 2017 vol. 376 no. 18 and Clinical Outcomes in Patients with Cardiovascular Disease Marc S. Sabatine, M.D., M.P.H., Robert P. Giugliano, M.D.,
More informationPage 1 of 13. Produced: July 2018 NHS Midlands and Lancashire CSU Not for Commercial Use
New Medicine Recommendation Evolocumab (Repatha SureClick ) For prevention of cardiac events in patients with CHD and a history of ACS, in combination with a statin Recommendation: Black Evolocumab is
More informationREVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative
More informationCase Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
Case Studies The Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk Kim K. Birtcher, PharmD, MS, AACC Clinical Professor University of Houston College of Pharmacy Houston,
More informationDrug Prior Authorization Guideline PCSK9 Inhibitors -
Drug Prior Authorization Guideline PCSK9 Inhibitors - REPATHA (evolocumab) PRALUENT (alirocumab) PA9911 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below Additional
More informationClinical Policy: Evolocumab (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017
Clinical Policy: (Repatha) Reference Number: ERX.SPMN.184 Effective Date: 01/2017 Last Review Date: Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationPCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019
PCSK9 and its Role in LDL Receptor Regulation Muscat, Oman - 9 February 2019 Professor Gilles Lambert, PhD LaboratoireInserm U1188 Universitéde la Réunion Faculté de Médecine Saint Denis de la Réunion,
More informationGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationJoshua Shepherd PA-C, MMS, MT (ASCP)
Joshua Shepherd PA-C, MMS, MT (ASCP) None What is Cholesterol? Why cholesterol is it important? Review the National Cholesterol Education Programs guidelines (NCEP-ATPIII) Discuss New guidelines from the
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationThe New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk
The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing
More informationCardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes
Cardiovascular outcomes trials with non-statin lipid-lowering drugs in diabetes FARIHA NAEEM, GERARD MCKAY, MILES FISHER REVIEW Abstract Statin therapy is proven to reduce cardiovascular morbidity and
More informationIsn't Xstatin 10mg good enough for the control of lipids for my patient? Do we need more?
Isn't Xstatin 10mg good enough for the control of lipids for my patient? Do we need more? Singhealth GP CME Symposium 2018 ~ Keep Well, Age Well Pan Pacific Hotel, Singapore 12 May 2018 Dr Farhad Fakhrudin
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationDeep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City
Deep Dive into Contemporary Cholesterol Management Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO CONSENSUS IN
More informationDrug Class Prior Authorization Criteria PCSK9 Inhibitors
Drug Class Prior Authorization Criteria PCSK9 Inhibitors Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationTHIERS CHAGAS BAHIA FOURIER- ESTUDO DE INIBIÇÃO DA PCSK9 EM PACIENTES DE ALTO RISCO CARDIOVASCULAR
FOURIER- ESTUDO DE INIBIÇÃO DA PCSK9 EM PACIENTES DE ALTO RISCO CARDIOVASCULAR THIERS CHAGAS BAHIA Global Core Content: Do not copy or distribute. Placeholder for Regional/Local Disclaimer. CONFLITO DE
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Repatha) Reference Number: HIM.PA.SP46 Effective Date: 01.01.18 Last Review Date: Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: PCSK9 inhibitors Rx.01.170 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.
More informationReducing Cardiovascular Risk Through Non-Statins. Kim K. Birtcher, PharmD Joseph Saseen, PharmD
Reducing Cardiovascular Risk Through Non-Statins Kim K. Birtcher, PharmD Joseph Saseen, PharmD Target Audience: Pharmacists ACPE#: 0202-0000-18-049-L01-P Activity Type: Application-based This activity
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationPCSK9 Inhibitors for Lowering Cholesterol: Ready for Prime Time?
Original Article Thomas Knickelbine, MD, FACC, FSCCT, FSCAI From: Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, MN Address for correspondence: Thomas Knickelbine, MD, FACC,
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationCommon Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2
Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More informationLDL-C treatment goals were introduced in the first National
Point/Counterpoint Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines Jennifer G. Robinson, Kausik Ray Abstract On the basis of accumulating evidence,
More informationPresenter Disclosure Information
1:45 2:45pm Lipid Management: A Primary Care Perspective Presenter Disclosure Information The following relationships exist related to this presentation: Richard F. Wright, MD, FACC, has no financial relationships
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationApproximately 34% of adults in the United States
RESEARCH Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationCardiovascular disease and diabetes Vascular harmony
Cardiovascular disease and diabetes 2018 Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics
More informationGlossary For TheFatNurse s For All Ages Series Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Apolipoprotein
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationHyperlipidemia: Past and Present. Rebecca Khaimova, PharmD The Brooklyn Hospital Center
Hyperlipidemia: Past and Present Rebecca Khaimova, PharmD The Brooklyn Hospital Center Rkhaimova@tbh.org Conflicts of Interest None to disclose Learning Objectives for Pharmacist Describe the pathophysiology
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
More informationEvidence-based Appraisal of the FOURIER Trial
evidence-based practice Evidence-based Appraisal of the FOURIER Trial Citation: Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl
More informationPraluent. Praluent (alirocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.06 Subject: Praluent Page: 1 of 10 Last Review Date: September 20, 2018 Praluent Description Praluent
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More informationDyslipidemia and Combination Therapy: A Framework for Clinical Decision Making
Dyslipidemia and Combination Therapy: A Framework for Clinical Decision Making Shashank Sinha, MD Pamela B. Morris, MD, FACC 8 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.08 Subject: Repatha Page: 1 of 8 Last Review Date: December 2, 2016 Repatha Description Repatha (evolocumab)
More informationProprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary
Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization with Quantity Limit Program Summary Proprotein Convertase Subtilisin/Kexin type 9(PCSK9) Inhibitors Prior Authorization
More informationLipid Control Today: Management within the Context of other Cardiovascular Risk Factors
Best Practices Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA, FASPC Lipidology & Cardiovascular Disease Prevention
More information